CRMD Quote, Financials, Valuation and Earnings

Protagenic Therapeutics has a net margin of 52.82% compared to Cormedix's net margin of --. Cormedix's return on equity of 23.7% beat Protagenic Therapeutics's return on equity of --.

Cormedix has a consensus price target of $18.83, signalling upside risk potential of 50.67%. On the other hand Protagenic Therapeutics has an analysts' consensus of -- which suggests that it could grow by 5954.05%. Given that Protagenic Therapeutics has higher upside potential than Cormedix, analysts believe Protagenic Therapeutics is more attractive than Cormedix.

Cormedix has a beta of 1.624, which suggesting that the stock is 62.377% more volatile than S&P 500. In comparison Protagenic Therapeutics has a beta of 0.371, suggesting its less volatile than the S&P 500 by 62.897%.

Cormedix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagenic Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cormedix pays -- of its earnings as a dividend. Protagenic Therapeutics pays out -- of its earnings as a dividend.

Cormedix quarterly revenues are $39.1M, which are larger than Protagenic Therapeutics quarterly revenues of --. Cormedix's net income of $20.6M is higher than Protagenic Therapeutics's net income of -$1.4M. Notably, Cormedix's price-to-earnings ratio is 56.82x while Protagenic Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cormedix is 9.35x versus 0.13x for Protagenic Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical has a net margin of 52.82% compared to Cormedix's net margin of -108.46%. Cormedix's return on equity of 23.7% beat Ultragenyx Pharmaceutical's return on equity of -205.06%.

Cormedix has a consensus price target of $18.83, signalling upside risk potential of 50.67%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $89.84 which suggests that it could grow by 146.01%. Given that Ultragenyx Pharmaceutical has higher upside potential than Cormedix, analysts believe Ultragenyx Pharmaceutical is more attractive than Cormedix.

Cormedix has a beta of 1.624, which suggesting that the stock is 62.377% more volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.250, suggesting its less volatile than the S&P 500 by 75%.

Cormedix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cormedix pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

Cormedix quarterly revenues are $39.1M, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $139.3M. Cormedix's net income of $20.6M is higher than Ultragenyx Pharmaceutical's net income of -$151.1M. Notably, Cormedix's price-to-earnings ratio is 56.82x while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cormedix is 9.35x versus 5.78x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Regulus Therapeutics has a net margin of 52.82% compared to Cormedix's net margin of --. Cormedix's return on equity of 23.7% beat Regulus Therapeutics's return on equity of --.

Cormedix has a consensus price target of $18.83, signalling upside risk potential of 50.67%. On the other hand Regulus Therapeutics has an analysts' consensus of $7.00 which suggests that it could fall by -14.22%. Given that Cormedix has higher upside potential than Regulus Therapeutics, analysts believe Cormedix is more attractive than Regulus Therapeutics.

Cormedix has a beta of 1.624, which suggesting that the stock is 62.377% more volatile than S&P 500. In comparison Regulus Therapeutics has a beta of 0.354, suggesting its less volatile than the S&P 500 by 64.643%.

Cormedix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regulus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cormedix pays -- of its earnings as a dividend. Regulus Therapeutics pays out -- of its earnings as a dividend.

Cormedix quarterly revenues are $39.1M, which are larger than Regulus Therapeutics quarterly revenues of --. Cormedix's net income of $20.6M is higher than Regulus Therapeutics's net income of -$9.6M. Notably, Cormedix's price-to-earnings ratio is 56.82x while Regulus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cormedix is 9.35x versus -- for Regulus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals has a net margin of 52.82% compared to Cormedix's net margin of 21.46%. Cormedix's return on equity of 23.7% beat Rigel Pharmaceuticals's return on equity of --.

Cormedix has a consensus price target of $18.83, signalling upside risk potential of 50.67%. On the other hand Rigel Pharmaceuticals has an analysts' consensus of $33.74 which suggests that it could grow by 73.39%. Given that Rigel Pharmaceuticals has higher upside potential than Cormedix, analysts believe Rigel Pharmaceuticals is more attractive than Cormedix.

Cormedix has a beta of 1.624, which suggesting that the stock is 62.377% more volatile than S&P 500. In comparison Rigel Pharmaceuticals has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.832%.

Cormedix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cormedix pays -- of its earnings as a dividend. Rigel Pharmaceuticals pays out -- of its earnings as a dividend.

Cormedix quarterly revenues are $39.1M, which are smaller than Rigel Pharmaceuticals quarterly revenues of $53.3M. Cormedix's net income of $20.6M is higher than Rigel Pharmaceuticals's net income of $11.4M. Notably, Cormedix's price-to-earnings ratio is 56.82x while Rigel Pharmaceuticals's PE ratio is 9.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cormedix is 9.35x versus 1.71x for Rigel Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.